Literature DB >> 7202134

Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.

H W Moser, A B Moser, K K Frayer, W Chen, J D Schulman, B P O'Neill, Y Kishimoto.   

Abstract

With a new method we measured the saturated very long chain fatty acids in the plasma of adrenoleukodystrophy (ALD) hemizygotes, ALD heterozygotes, and controls. ALD hemizygotes showed increased levels of hexacosanoate (C26 fatty acid) which represented 0.081 +/- 0.0066% (SEM) of total fatty acids, compared to 0.015 +/- 0.0032% in the controls. C25, C24, and C23 fatty acids were also increased, but the C22 and C20 fatty acids were normal. C26 levels were also increased in most ALD heterozygotes, with a mean level 0.057 +/- 0.0063% of total fatty acids. The technique can be used for diagnosis and carrier identification, and in the evaluation of therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7202134     DOI: 10.1212/wnl.31.10.1241

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  83 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  X-linked adrenoleukodystrophy: first report of the Italian Study Group.

Authors:  A Di Biase; S Salvati; C Avellino; M Cappa; E Bertini; I Moroni; M Rimoldi; G Uziel
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 3.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 4.  Peroxisomal disorders: clinical, biochemical, and molecular aspects.

Authors:  R J Wanders
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

5.  Clinical quiz. Addison's disease.

Authors:  K E Meyers; P D Thomson; J Cartwright
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 6.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

7.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

8.  A family with adrenoleucodystrophy.

Authors:  R P Singh; S Deshpande; R K Marwaha; K Garg
Journal:  Indian J Pediatr       Date:  1989 Sep-Oct       Impact factor: 1.967

9.  Adrenoleukodystrophy without adrenal insufficiency and its magnetic resonance imaging.

Authors:  H Nishio; S Kodama; T Tsubota; T Takumi; T Takahashi; S Yokoyama; T Matsuo
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

10.  Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study.

Authors:  Björn M van Geel; Bwee Tien Poll-The; Aad Verrips; Jaap-Jan Boelens; Stephan Kemp; Marc Engelen
Journal:  J Inherit Metab Dis       Date:  2014-12-09       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.